Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017 Jul 26, 2017
Nanjing Frontier Acquires Rights to Rockefeller University HIV/AIDS Antibody Jul 25, 2017 Life Science
DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM Jul 25, 2017 Life Science
Cardinal Health Plans $1.5 Billion Sale of China Drug Distribution Business Jul 20, 2017 Life Science
RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D Jul 19, 2017 Life Science
DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM Jul 19, 2017 Life Science
RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease Jul 13, 2017 Life Science
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman Jul 12, 2017 Life Science
Resverlogix and Hepalink Start Taiwan/China Trial of CVD/Diabetes Treatment Jul 11, 2017 Life Science